Theoretical and Natural Science

- The Open Access Proceedings Series for Conferences

Theoretical and Natural Science

Vol. 24, 20 December 2023

Open Access | Article

The implication and advantages of small-molecule drug

Tianyu Lu * 1 , Jiayi Yang 2
1 University of Shanghai for Science and Technology
2 University of California(Davis)

* Author to whom correspondence should be addressed.

Theoretical and Natural Science, Vol. 24, 76-80
Published 20 December 2023. © 2023 The Author(s). Published by EWA Publishing
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Citation Tianyu Lu, Jiayi Yang. The implication and advantages of small-molecule drug. TNS (2023) Vol. 24: 76-80. DOI: 10.54254/2753-8818/24/20231103.


Small-molecule drugs are a widely used and theoretically mature therapeutic approach. Due to their small size and stable chemical structure, they can better penetrate the cell membrane and directly reach the intercellular target side, and their pharmacokinetics are more predictable. Many small-molecule drugs have contributed to medical advances and improved the lives of patients. At present, they have shown relatively high efficiency in the targeted treatment of a variety of diseases. In this review, we highlight their mechanisms and possibilities in the treatment of individual human diseases such as Alzheimer’s disease, cancer, and Covid-19 by comparing them with traditional macromolecular drugs, as well as the percentage of small molecule drugs used in current drugs, specific improvements in patient efficacy, or new insights into the mechanisms of action of small molecule drugs. For the prospects of small molecule drugs, new drugs will also emerge along with new challenges.


Small Molecule Drug, Alzheimer’s Disease, Cancer, Covid, Tacrine


1. QIN Tao & MA Cui-cui.(2011).Exploring New Ideas of Drug Development from Small M olecule Drugs.Journal of Beijing Union University (Natural Sciences)(03),63-66. doi:10.16255/j.cnki.ldxbz.2011.03.016.

2. Dong Bin, Research Progress in Alzheimer’s Drugs, Pharmaceutical and Chemical, 2020,4:1003-6490(2020)04-0221-02

3. GUO Ying-shan & ZHANG Zhong-min.(2008). Anti-AD Agents-New Developments of Cholinesterase Inhibitors. Coal and Chemical Industry(03),14-16.

4. YE Min-zhong,CHENG Zhi-yi & PI Rong-biao.(2008).Development of the multi-target-directed acetylcholinesterase inhibitors based on tacrine. Chinese Pharmacological Bulletin(12),1549-1554.

5. LIU Miao,CHEN Hong-ge,WU Rong-rong & WEI Zhen-man.(2009).Research progress of sorafenib in the treatment of liver cancer. Herald of Medicine(12),1562-1564.

6. Garnett, M. J., & Marais, R. (2004). Guilty as charged. Cancer Cell, 6(4), 313–319.

7. Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J. F., De Oliveira, A. C. S., Santoro, A., Raoul, J., Forner, A., Schwartz, M., Porta, C., Zeuzem, S., Bolondi, L., Greten, T. F., Galle, P. R., Seitz, J. F., Borbath, I., Häussinger, D., . . . Bruix, J. (2008). Sorafenib in advanced hepatocellular carcinoma. The New England Journal of Medicine, 359(4), 378–390.

8. Cheng, A., Kang, Y., Chen, Z., Tsao, C., Qin, S., Kim, J., Burock, K., Zou, J., Voliotis, D., & Guan, Z. Z. (2008). Randomized phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma. Journal of Clinical Oncology, 26(15_suppl), 4509.

9. Leal, C., Magalhães, C. R., Barbosa, D. S., Aquino, D., Carvalho, B. B. M., Balbi, E., Pacheco, L., Perez, R. M., De Tarso Aparecida Pinto, P., & Setúbal, S. (2018). Survival and tolerance to sorafenib in Child-Pugh B patients with hepatocellular carcinoma: a prospective study. Investigational New Drugs, 36(5), 911–918.

10. Zhong, L., Zhao, Z., Peng, X., Zou, J., & Yang, S. (2022). Recent advances in small-molecular therapeutics for COVID-19. Precision Clinical Medicine, 5(4).

11. Zhang, J., Li, Y., Wang, L., Liu, H., Lu, S., Liu, Y., Li, K., Liu, B., Li, S., Shao, F., Wang, K., Sheng, N., Li, R., Cui, J., Sun, P., Ma, C., Zhu, B., Wang, Z., Wan, Y., Jiang, J. (2021). Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients. Signal Transduction and Targeted Therapy, 6(1).

12. Yu, B., & Chang, J. (2020). Azvudine (FNC): a promising clinical candidate for COVID-19 treatment. Signal Transduction and Targeted Therapy, 5(1).

13. Yu, B., & Chang, J. (2022). The first Chinese oral anti-COVID-19 drug Azvudine launched. The Innovation, 3(6), 100321.

14. Chang, J. (2022). 4′-Modified nucleosides for Antiviral Drug Discovery: Achievements and Perspectives. Accounts of Chemical Research, 55(4), 565–578.

Data Availability

The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:

1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.

2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.

3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).

Volume Title
Proceedings of the 3rd International Conference on Biological Engineering and Medical Science
ISBN (Print)
ISBN (Online)
Published Date
20 December 2023
Theoretical and Natural Science
ISSN (Print)
ISSN (Online)
20 December 2023
Open Access
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

Copyright © 2023 EWA Publishing. Unless Otherwise Stated